Spago Nanomedical has initiated the clinical trial SPAGOPIX-01
Spago Nanomedical AB (publ) has conducted site initiation visit at the Uppsala University Hospital in Uppsala and formally opened the first clinical trial with the tumor selective contrast agent SpagoPix (SN123D). The trial will include up to 20 patients with confirmed breast cancer.The primary objective with the trial is to document safety, but another important objective is to investigate SN132D´s MRI-enhancing effects when used clinically in patients with solid tumors. ”There is need for better contrast agents for MRI of solid tumors. If SN132D provides good images, it can become an